We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.90 | 1.06% | 276.84 | 276.81 | 276.94 | 276.91 | 273.3811 | 274.18 | 611,406 | 17:36:22 |
From May 2019 to May 2024
By Kimberly Chin
Amgen Inc. has received a breakthrough therapy designation by the U.S. Food and Drug Administration for a treatment that helps patients with advanced gastric or gastroesophageal cancer.
The drug, bemarituzumab, has shown clinically meaningful outcomes in patients with this kind of cancer, the company said. The designation, which helps expedite the development and regulatory review of medicines, paves the way for the drug to be used as a first-line treatment in combination with modified fluoropyrimidine, leucovorin and oxaliplatin, or FOLFOX6, the company said.
Bemarituzumab is the second therapy in Amgen's oncology portfolio to receive such designation in the past six months, Amgen said.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 19, 2021 16:37 ET (20:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
